期刊文献+

HIV-1 p24和gp41融合基因表达载体的构建及融合蛋白的表达纯化 被引量:2

Construction,expression and purification of HIV-1 p24-gp41 fusion protein in E.coli
原文传递
导出
摘要 目的用基因重组技术将HIV-1 p24基因以及gp41基因具有抗原线性中和表位的部分重组连接,构建重组质粒,并在大肠埃希菌中高效表达融合蛋白。方法设计带有酶切位点的引物,分别PCR扩增p24和gp41两个基因,将它们分别连接到pMD18-T载体中,测序验证后,挑选出含有目的基因的正确克隆。将p24片段酶切后连接到gp41基因所在的pMD18-T载体中,再将连接后的两个基因酶切,重新连接到pET21a表达载体中。将表达载体转染大肠埃希菌诱导表达,经Western-blot验证表达正确。结果融合蛋白p24-gp41在大肠埃希菌中高效表达。结论融合蛋白p24-gp41可以在pET21a表达载体中高效表达。 Objective To construct recombinant plasmid with p24 and gp41 gene, express fusion protein in E. coli. Methods To design primer with restriction endonuclease position,and amplify p24 and gp41 by RT-PCR, link both into pMD18-T vector. To choose correct clone with target gene. Then p24 fragment will be cleaved and linked into pMD18 T vector within gp41 gene. Both post-linked gene will be cleaved and linked into pET21a vector. The vector will be transformed into E. coll. And protein is highly effective expressed in E coli. Western blotting proved that the expressed product could react with 6 × his antibody. Result Fusion protein p24-gp41 is highly effective expressed in E. eoli. Conclusion Fusion protein p24-gp41 is highly effective expressed in E. coli in pET21a vector.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2005年第3期170-173,共4页 Chinese Journal of Infectious Diseases
基金 教育部归国人员基金资助(教育部26)
关键词 HIV核心蛋白质p24 HIV包膜蛋白质gp41 基因表达 重组融合蛋白质类 基因表达载体 gp41基因 p24基因 HIV-1 融合蛋白 WESTERN-BLOT HIV core protein p24 HIV envelope protein gp41 Gene expression Recombinant fusion proteins
  • 相关文献

参考文献9

  • 1Sastry L, Xu Y, Johnson T, et al. Certification assays for HIV-1-based vectors:frequent passage of gag sequences without evidence of replication-competent viruses. Mol Ther,2003,8:830-839. 被引量:1
  • 2Agrawal L, Haq W, Hanson CV, et al. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-1 env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J Immune Based Ther Vaccines,2003,1:5. 被引量:1
  • 3Joshua MN, Qi Y, Fu-Hua Y, et al. Compairison of the biological activities of human immunodeficiency virus 1 p24 and gp41 expressed in Spodoptera frugiperda cells by use of bac-to-bac system. Acta Virol,2000,44:125-130. 被引量:1
  • 4Cavacini LA, Kuhrt D, Duval M, et al. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res Hum Retroviruses,2003,19:785-792. 被引量:1
  • 5Bahbouhi B, al-Harthi L. Enriching for HIV-infected cells using anti-gp41 antibodies indirectly conjugated to magnetic microbeads. Biotechniques,2004,36:139-147. 被引量:1
  • 6尹春煜,卢洪洲,蒋卫民,胡越凯,赵清霞,何云,潘孝彰,翁心华.HIV-1gag基因p24编码区的变异性分析[J].复旦学报(医学版),2004,31(4):371-374. 被引量:1
  • 7Kong WP, Huang Y, Yang ZY. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol, 2003,77:12764-12772. 被引量:1
  • 8He Y, Vassell R, Zaitseva M, et al. Peptides trap the human immunodeficiency virus type 1 envelop glycoprotein fusion intermediate at two sites. J Virol,2003,77:1666-1671. 被引量:1
  • 9LaCasse RA, Follis KE. Trahey I, et al. Fusion-competent vaccines:broad neutralization of primary isolates of HIV. Science,1999,283:357-362. 被引量:1

二级参考文献9

  • 1Wain-Hobson S.The fastest genome evolution ever described:HIV variation in situ.Curr Opin Genet Dev,1993,3:878 被引量:1
  • 2Vartanian JP,Meyerhans A,Sala M,et al.G→A hypermutation of the HIV-1 genome:evidence for dCTP pool imbalance during reverse transcription.Proc Natl Acad Sci US,1994,91:3092 被引量:1
  • 3Bieniasz PD,Cullen BR.Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.J Virol,2000,74:9868 被引量:1
  • 4Zhang Y,Barklis E.Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation.J Virol,1997,71:6765 被引量:1
  • 5Moss RB,Brandt C,Giermakowska WK,et al.HIV-specific immunity during structured antiviral drug treatment interruption.Vaccine,2003,21(11-12):1066 被引量:1
  • 6McCutchan FE,Artenstein AW,Sanders BE,et al.Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa.J Virol,1996,70:3331 被引量:1
  • 7Yoshimura FK,Diem K,Learn GH,et al.Intrapatient sequence varia-tion of the gag gene of human immunodeficiency virus type 1 plasma virions.J Virol,1996,70:8879 被引量:1
  • 8Graf M,Shao Y,Zhao Q,et al.Cloning and characterization of a virtually full-length HIV type 1 genome from a subtype B'-Thai strain representing the most prevalent B-clade isolate in China.AIDS Res Hum Retroviruses,1998,14(3):285 被引量:1
  • 9Rouzine IM,Coffin JM.Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus.J Virol,1999,73:8167 被引量:1

同被引文献17

  • 1艾菁,王丽梅,夏威,耿美玉.Tat蛋白结构与功能的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):133-135. 被引量:17
  • 2Chaloin O, Peter JC, Briand JP, et al. The N-terminus of HIV 1 Tat protein is essential for Tat TAR RNA interaction. Cell Mol Life Sci, 2005,62 :355 361. 被引量:1
  • 3Kittiworakarn J, Lecoq A, Moine G, et al. HIV1 Tat raises an adjuvant free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J BiolChem, 2006,281:3105 -3115. 被引量:1
  • 4Belliard G, Hurtrel B, Moreau E, et al. Tat neutralizing versus Tat protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine, 2005,23:1399 -1407. 被引量:1
  • 5Caputo A, Brocca-Cofano E, Castaldello A, et al. Characterization of immune responses elicited in mice by intranasal co immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat labile Esckerichia coli enterotoxin. Vaccine, 2008,26: 1214-1227. 被引量:1
  • 6Halsey RJ, Tanzer FL, Meyers A, et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res, 2008,133:259-268. 被引量:1
  • 7Wyatt LS, Belyakov IM, Earl PL, et al. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology, 2008, 372: 260-272. 被引量:1
  • 8Lecoq A, Moine G, Bellanger L, et al. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligandstabilizing strategy. Vaccine, 2008,26:2615- 2626. 被引量:1
  • 9Campbell GR, Senkaali D, Watkins J, et al. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine, 2007,25:8441- 8447. 被引量:1
  • 10Pugliese A, Vidotto V, Beltramo T,et al. A review of HIV- 1 Tat protein biological effects. Cell Biochem Funct, 2005, 23:223- 227. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部